Ulisse Biomed Future Growth
Future criteria checks 2/6
Ulisse Biomed is forecast to grow earnings and revenue by 36.9% and 46.1% per annum respectively.
Key information
36.9%
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 39.4% |
| Revenue growth rate | 46.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 31 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2 | -3 | 0 | N/A | 1 |
| 12/31/2025 | 2 | -3 | 0 | N/A | 1 |
| 12/31/2024 | 1 | -6 | -3 | N/A | 1 |
| 6/30/2024 | 0 | -7 | N/A | N/A | N/A |
| 3/31/2024 | 0 | -6 | N/A | N/A | N/A |
| 12/31/2023 | 0 | -5 | N/A | N/A | N/A |
| 9/30/2023 | 0 | -3 | N/A | N/A | N/A |
| 6/30/2023 | 0 | -2 | -2 | -1 | N/A |
| 3/31/2023 | 0 | -1 | -1 | -1 | N/A |
| 12/31/2022 | 0 | -1 | -1 | -1 | N/A |
| 9/30/2022 | 0 | -1 | N/A | N/A | N/A |
| 6/30/2022 | 0 | -1 | -2 | -1 | N/A |
| 3/31/2022 | 0 | -1 | -2 | -1 | N/A |
| 12/31/2021 | 0 | -1 | -1 | 0 | N/A |
| 9/30/2021 | 0 | 0 | N/A | N/A | N/A |
| 6/30/2021 | 1 | 0 | 0 | 1 | N/A |
| 3/31/2021 | 1 | 0 | 0 | 0 | N/A |
| 12/31/2020 | 1 | 0 | -1 | -1 | N/A |
| 12/31/2019 | 0 | -1 | 0 | 0 | N/A |
| 12/31/2018 | 0 | -2 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8XX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 8XX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 8XX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 8XX's revenue (46.1% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 8XX's revenue (46.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 8XX's Return on Equity is forecast to be high in 3 years time